MannKind Corp. (MNKD) News Headlines

▮ More

Date

Headline

11/9/2021 4:35:25 PM MannKind Corp. Q3 adjusted earnings Beat Estimates

11/9/2021 6:00:20 AM MannKind Q3 21 Earnings Conference Call At 5:00 PM ET

10/4/2021 7:06:44 AM MannKind Enrolls First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population

9/7/2021 6:02:47 AM United Therapeutics Presents Tyvaso DPI BREEZE Clinical Data At European Respiratory Society International Congress 2021

8/11/2021 5:41:42 PM MannKind Corp. Q2 adjusted earnings Miss Estimates

8/11/2021 6:15:08 AM MannKind Q2 21 Earnings Conference Call At 5:00 PM ET

8/4/2021 7:50:28 AM MannKind Partners With NRx Pharma To Explore Dry Powder Formulation Of ZYESAMI

8/4/2021 6:54:10 AM MannKind Partners With NRx Pharm To Explore Dry Powder Formulation Of ZYESAMI Based On Technosphere Platform

6/16/2021 12:12:46 PM MannKind Says FDA Grants Priority Review For Tyvaso DPI NDA

6/16/2021 11:02:35 AM MannKind : FDA Accepts For Priority Review Of NDA For Tyvaso DPI For Treatment Of PAH And PH-ILD

6/3/2021 6:03:41 AM MannKind Presents A Post Hoc Analysis From STAT Study

4/19/2021 7:11:25 AM United Therapeutics Files New Drug Application For Tyvaso DPI- Quick Fats

4/19/2021 6:08:32 AM MannKind, United Therapeutics Reach Milestone In Development Of Tyvaso DPI

3/2/2021 6:36:16 AM MannKind Prices Upsized $200.0 Mln Convertible Senior Notes Offering

3/2/2021 12:51:09 AM FDA Says No To ATNX And CRMD, Morphic Jumps On IBD Trial Data, INO's REVEAL 1 Meets Goals

3/1/2021 7:14:35 AM MannKind Intends To Offer $150.0 Mln Of Convertible Senior Notes Due 2026

2/25/2021 8:23:41 AM MannKind Corp. Posts Adj. Loss In Q4

2/25/2021 8:09:42 AM MannKind Q4 Loss/Shr $0.11 Vs Loss $0.07 Last Year

2/24/2021 8:01:34 AM Vertice Launches THYQUIDITY Oral Solution

12/10/2020 8:57:37 AM MannKind Appoints James Shannon As Chairman

Mannkind Corp. (MNKD)